Type Description Clause Samples

Type Description. Visit 1 Within 28 days of Visit 2 Screening Outpatient visit; must fast (no food or drink other than water) for at least 8 hours before visit Visit 2 Check in Day -1; Check out Day 21 Dosing on Day 1 Dosing on Day 8 Dosing on Day 15 In house stay (21 days); must fast (no food or drink other than water) for at least 8 hours before check-in Visit 3 Day 30 Follow-up Outpatient visit Visit 4 Day 45 Follow-up (End of Study) Outpatient visit; must fast (no food or drink other than water) for at least 8 hours before visit

Type Description. 1 Delivery schedule line number Att Identifier Identifier The unique number given by the issuer to identify a delivery schedule line within a Delivery schedule message.

Type Description. Visit 1 Within 28 days of Visit 2 Screening Outpatient visit; must fast (no food or drink other than water) for at least 8 hours before visit Visit 2 Check in Day -1; Check out Day 7 Dosing on Day 1 In house stay (7 days); must fast (no food or drink other than water) for at least 8 hours before check-in Visit 4 Day 14 Follow-up Outpatient visit Visit 5 Check in Day 21; Check out Day 28 Dosing on Day 22 In house stay (7 days); must fast (no food or drink other than water) for at least 8 hours before check-in Visit 6 Day 35 Follow-up Outpatient visit Visit 7 Day 52 Follow-up (End of Study) Outpatient visit; must fast (no food or drink other than water) for at least 8 hours before visit The decision for when you can participate in another study is determined by the drug safety information gathered from the previous study. Usually, you can participate in another study as soon as 30 days after you received the last dose of drug in the study you were in. This information is true for most drugs. Some drugs may stay in your body longer and that may mean you may have to wait longer before starting another study. These results are usually only known after the last blood sample taken from you is tested to look for left-over drug. We will always make this information available to you as soon as we know. Our goal is to keep you from doing anything that may be potentially harmful to you. Your safety while participating in these studies is our primary concern. You cannot be enrolled in the study if, at screening you: • Report a history of allergic reactions or oversensitivity to drugs like rezafungin or the inactive ingredients (mannitol, polysorbate 80, histidine) of the injectable form of rezafungin (Rezafungin for Injection); • experience symptoms of an illness within 14 days before the first dose of study drug, or if the Study Doctor feels you are not in good health; • if you weigh less than 50 kg (110 lbs.) and/or have a body mass index (BMI) calculated from your height and weight that is less than 18.5 kg/m2 or more than 35.0; • have a positive HIV or hepatitis test result, abnormal laboratory test results that are not due to a transient (passing) condition, or an abnormal electrocardiogram (ECG); • Are pregnant or planning to become pregnant during the study or a minimum of 30 days after the study, or if you are breastfeeding, or if you have any medical conditions that could make it potentially unsafe for you to participate in the study (for females); • are plann...

Type Description. OHIP Number Each eligible resident of the Province of Ontario that registers for the Ontario Health Insurance Plan (OHIP) is assigned a unique 10-digit health number, which may be followed by a single letter or two letter version code. Employee Number In Canada, an Employee Number is a unique number ascribed to each employee by employers for record-keeping and bookkeeping purposes. SIN A Social Insurance Number (SIN) is a 9-digit number required to work in Canada and/or access government programs and benefits. Financial Information In the context of this review, Financial Information will include any of the following: (i) a credit card number or (ii) bank account number. Address It is possible that some documents may not include an Affected Class Member’s name, but may have their mailing address or an email address on the document. II – Preparation of the Independent Review Deliverables Following completion of the Independent Review, the Independent Reviewer shall prepare two deliverables, which will be provided to Class Counsel and to the lawyers for the Defendant.

Type Description. 2 Legal provisions cannot be enforced 3 Legal provisions are not fit for purpose to protect the fundamental right at stake Let me briefly explain the need to investigate these three types of legal problems in particular. Both the right to privacy and data protection are fundamental rights in the EU.634 Violations of fundamental rights, which constitute Type 1 legal problems, must be prevented. For example, unsupervised ML approaches process personal data for inexplicit purposes – the processing itself determines the pur- pose and future use of the personal data. Such processing violates the purpose limitation principle, which constitutes a Type 1 legal problem. Type 2 legal problems, namely, when legal provisions cannot be enforced, are not acceptable either because they lead to negative consequences for the de facto protection of fundamental rights. For example, the unclear substantive meaning of the fairness principle reduces legal certainty and makes it less likely that this principle will be enforced by means 633 Admittedly, this is not a traditional data protection principle. Nonetheless, it could be regarded as a principle in a broader sense, which then also aligns with the approach taken in this chapter. 634 Article 7 and 8 CFREU. of private litigation and by supervisory authorities, which leads to Type 2 problems. Furthermore, Type 3 legal problems, namely, legal provisions that are not fit for purpose, point to the shortcomings of the current legal framework. Legal provisions are not fit for purpose, for instance, when they fail to achieve legislative aims, are not effective or create a gap of protection. For example, the principle that special categories of personal data receive enhanced protection and the legislator’s approach to exhaustively enumerate special data cause a Type 3 legal problem. This approach does not keep up with technological developments facilitated by AI. It leads to significant gaps of protection, for ex- ample, regarding the processing of new types of sensitive personal data generated by AI, such as emotion data, neurodata and mental data. Insights about this type of legal problems are essential when considering how the legal problems should be addressed, which is the aim of Subquestion 5 (see Chapter 6). As indicated in Section 1.4, the scope of this thesis is limited to legal problems related to the funda- mental rights to privacy and data protection. Thus, this chapter identifies legal problems arising pri- ▇▇▇▇▇▇ from t...

Type Description. The uncertainty associated with radiometric responsivity of an OCR shall be estimated and delivered to FRMOCnet, including: the quantification of uncertainties from the radiometric calibration laboratory and their propagation; an estimation of any temporal changes in responsivity between such calibrations; and, for in-water measurements, (residual) uncertainties associated with immersion factors and possible pressure effects. The FRM4SOC-2 project deliverable D-10, using ideas from chapters 3.2, 3.4, 3.10 and 3.13 of [20], provides guidance on how to do this for the TRIOS/RAMSES and Seabird/HyperOCR OCR, while the FRM4SOC-2 project deliverable D-12 provides guidance on how to perform the laboratory measurements themselves.

Type Description. Address identification Att Identifier Identifier The unique identification of a location based on the Duns (Duns & Bradstreet) number of the company followed by four numeric digits. 1 Address line one Att Text Line one The first line of the address.